Recalcitrant Acneiform Eruption Revealing Behçet’s Disease: A Case with Late but Successful Response to Adalimumab
Behçet's disease is a systemic vasculitis with a chronic-relapsing course, which can lead to significant morbidity and mortality. From the often-compelling challenge of making a prompt diagnosis comes the difficulty in its treatment. We report the case of a patient with an acneiform skin eruption revealing Behçet's disease that was refractory to conventional therapy and later completely responded to adalimumab. Although randomized controlled clinical trials are lacking in the literature, there is already significant evidence supporting anti-TNF agents as a major therapeutic advance in Behçet's disease, particularly in cases that are severe, refractory or intolerant to classical immunosuppression.
International Study Group Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078-1080.
International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338-347.
Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60-76.
Krause I, Uziel Y, Guedj D, Mukamel M, Molad Y, Amit M, et al. Mode of presentation and multisystem involvement in Behçet’s disease: the influence of sex and age of disease onset. J Rheumatol. 1998;25:1566-1569.
Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, et al. Mortality in Behçet’s disease. Arthritis Rheum. 2010;62:2806-2812.
Sfikakis PP. Behcet’s disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis. 2002;61(2):51-53.
Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61-70.
Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. J Autoimmun. 2015;62:67-74.
Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, et al. Behçet's disease-a contemporary review. J Autoimmun. 2009;32(3-4):178-188.
Kalkan G, Karadag AS, Astarci HM, Akbay G, Ustun H, Eksioglu M. A histopathological approach: when papulopustular lesions should be in the diagnostic criteria of Behçet's disease? J Eur Acad Dermatol Venereol. 2009;23(9):1056-1060.
Cho S, Kim J, Cho SB, Zheng Z, Choi MJ, Kim DY, et al. Immunopathogenic characterization of cutaneous inflammation in Behçet's disease. J Eur Acad Dermatol Venereol. 2014;28(1):51-57.
Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agentes in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785-796.
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-1662.
Olivieri I, Leccese P, D'Angelo S, Padula A, Nigro A, Palazzi C, et al. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29(4):S54-57.
Aikawa NE, Gonçalves C, Silva CA, Gonçalves C, Bonfá E, de Carvalho JF. Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet’s disease. Rheumatol Int. 2011;31(8):1097-1099.
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).